Related Experiment Video
Updated: Oct 2, 2025
08:59
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
10.8K
Skene's Gland Malignancy: A Case Report and Systematic Review
Emily A Slopnick1, Christina Bagby2, Amr Mahran3
1Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Urology
|February 22, 2022
Summary
This study reviews 15 cases of Skene's gland malignancy, finding it resembles prostate adenocarcinoma. Local excision is common, with androgen deprivation therapy showing promise for treating this rare cancer.
Area of Science:
- Urogynecology
- Oncology
- Pathology
Background:
- Skene's gland malignancy is rare, with limited published data.
- Understanding treatment and outcomes is crucial for patient management.
Observation:
- A systematic literature review identified 15 cases of Skene's gland malignancy from 1974 to 2022.
- The median patient age was 71, with presentations including asymptomatic periurethral lesions and bleeding.
- Elevated prostate-specific antigen (PSA) was noted in 8 cases, normalizing post-treatment.
Findings:
- All cases were histologically consistent with adenocarcinoma resembling prostate.
- Local excision was the most frequent treatment, with varied approaches including surgery and radiation.
- No recurrence or mortality was observed in the median 11.5-month follow-up.
Implications:
- Skene's gland adenocarcinoma requires a high index of suspicion, especially with elevated PSA.
- Local excision appears effective, and androgen deprivation therapy is a potential new treatment modality.
- Further research is needed to establish optimal treatment protocols for this rare malignancy.
